CTLA4 Polymorphisms and De Novo Malignancy Risk after Renal Transplantation in Chinese Recipients

Table 1

Comparison of clinical characteristics between patients with tumor and nontumor.

Characteristic	Patients with tumor ()	Patients with nontumor ()	P value
Mean age ± SD	40.717 ± 9.474	40.175 ± 10.100	0.712
Sex
Male	35 (66.04)	253 (61.56)	0.552
Female	18 (33.96)	158 (38.44)
Primary diseases
Chronic glomerulonephritis	47 (88.68)	377 (91.73)	0.458
Polycystic kidney	1 (1.89)	17 (4.14)	0.426
Pyelonephritis	2 (3.77)	14 (3.40)	0.891
Aristolochic acid nephropathy	3 (5.66)	3 (0.73)	0.003
Dialysis time (≥3 years)	23	193	0.625
Number of HLA-mismatch	2.57 ± 1.029	2.47 ± 0.806	0.514
Real transplantation
Living/cadaver	5/48	46/365	0.819
Antibody induction therapy	17	140	0.774
Immunosuppressant regimens
CsA + MMF + Pred	34 (64.15)	272 (66.18)	0.760
TAC + MMF + Pred	19 (35.85)	139 (33.82)
Blood transfusion	5	52	0.658
Rejection
AR/non-AR	11/42	53/358	0.137

CsA: cyclosporine, MMF: mycophenolate mofetil, Pred: prednisone, TAC: tacrolimus, AR: acute rejection, non-AR: nonacute rejection, and tumor: drug induced liver injury.